8-KOther EventsExhibits & Filings

Guardant Health, Inc. 8-K Report, Corporate Update (Jan 7, 2022)

Filed January 7, 2022For Securities:GH

Summary

Guardant Health, Inc. (GH) has entered into a definitive Settlement and License Agreement with Foundation Medicine, Inc. (FMI), a subsidiary of Roche Holdings, Inc. This agreement resolves all pending patent litigation between the two companies. As part of the settlement, FMI will pay Guardant Health $25 million upfront and provide future royalties for the duration of the licensed patents. In exchange, Guardant Health is granting FMI a non-exclusive license to a specific subset of its patents. This settlement is a significant positive development for Guardant Health, as it eliminates a major legal overhang and provides immediate financial benefit through the cash payment and potential future royalty streams. The resolution of patent disputes allows both companies to focus on their respective businesses and innovation in the oncology diagnostics space. Investors should view this as a de-risking event that removes uncertainty and strengthens the company's financial position.

Key Highlights

  • 1Guardant Health and Foundation Medicine (FMI) have finalized a Settlement and License Agreement, resolving all patent litigation.
  • 2FMI will pay Guardant Health $25 million upfront as part of the settlement.
  • 3Guardant Health will receive future royalties from FMI for the remaining term of the licensed patents.
  • 4Guardant Health grants FMI a non-exclusive license to a defined subset of Guardant Health's patents.
  • 5The agreement effectively ends all ongoing patent disputes between the two companies.
  • 6This settlement removes a significant legal and financial uncertainty for Guardant Health.

Frequently Asked Questions

The settlement provides Guardant Health with an immediate $25 million cash payment and the potential for future royalty revenue from FMI, thereby improving its financial position and reducing uncertainty.

Guardant Health is granting FMI a non-exclusive license to a specific set of Guardant Health's patents. The terms of the license are defined within the agreement.

This settlement is crucial as it resolves ongoing patent litigation, a potentially costly and distracting issue. It removes a significant legal overhang, allowing the company to focus more resources on its core business operations and innovation, and it provides a financial benefit.

With the finalization of the Settlement and License Agreement, all pending patent litigation between Guardant Health and FMI will be dismissed. The company's press release mentions 'final court approval of the settlement and entry into a definitive settlement agreement' as forward-looking statements, suggesting the process is substantially complete but subject to formal court action.